US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Skye Bioscience Inc.

2.43

+0.280013.02%

Post-market: 2.40-0.0300-1.23%19:54 EDT

Volume:342.98K

Turnover:823.04K

Market Cap:75.29M

PE:-2.93

High:2.48

Open:2.17

Low:2.17

Close:2.15

Loading ...

Overview Company News Filings

Skye Bioscience Inc. Unveils Presentation on Innovative CB1 Antibody for Tackling Obesity

Skye Bioscience Inc - Data From 26-Week Treatment Period Expected Late Q3 or Early Q4 2025

THOMSON REUTERS

Skye Bioscience Establishes Partnership With Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

THOMSON REUTERS

Skye Bioscience- to Fund Arecor's Development Activities With Option to License Rights to New Proprietary Formulation of Nimacimab

THOMSON REUTERS

Piper Sandler Sticks to Its Buy Rating for Skye Bioscience (SKYE)

BRIEF-Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Oppenheimer Adjusts Skye Bioscience Price Target to $17 From $21, Maintains Outperform Rating

MT Newswires Live

Piper Sandler Reaffirms Their Buy Rating on Skye Bioscience (SKYE)

Skye Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary

Skye Bioscience Q1 EPS $(0.28) Beats $(0.31) Estimate

Skye Bioscience Inc: Qtrly Loss per Share $0.28

THOMSON REUTERS

Skye Bioscience Inc Q1 Shr View $-0.29 -- Lseg Ibes Data

THOMSON REUTERS

Press Release: Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

Skye Bioscience Inc expected to post a loss of 29 cents a share - Earnings Preview

Skye Bioscience to Participate in May Investment and Medical Conferences

Skye Bioscience announces inducement grant under Nasdaq listing rule

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE-Dow, Nike, Coty

Skye Bioscience Stock Rises on Preclinical Data for Weight Loss Drug

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SKYE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SKYE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","market":"US","secType":"STK","nameCN":"Skye Bioscience Inc.","latestPrice":2.43,"timestamp":1749240000000,"preClose":2.15,"halted":0,"volume":342981,"hourTrading":{"tag":"盘后","latestPrice":2.4,"preClose":2.43,"latestTime":"19:54 EDT","volume":7882,"amount":19000.325,"timestamp":1749254070956},"delay":0,"floatShares":16089235,"shares":30984358,"eps":-0.829901,"marketStatus":"Market Closed","change":0.28,"latestTime":"06-06 16:00:00 EDT","open":2.17,"high":2.48,"low":2.17,"amount":823042.5881940001,"amplitude":0.144186,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.829901,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"symbolChange":{"newSymbol":"SKYED","executeDate":"2023-09-08"},"adr":0,"exchange":"NASDAQ","adjPreClose":2.15,"preHourTrading":{"tag":"盘前","latestPrice":2.25,"preClose":2.15,"latestTime":"09:18 EDT","volume":922,"amount":2036.0950120000002,"timestamp":1749215922366},"postHourTrading":{"tag":"盘后","latestPrice":2.4,"preClose":2.43,"latestTime":"19:54 EDT","volume":7882,"amount":19000.325,"timestamp":1749254070956},"volumeRatio":1.1866023444132845,"impliedVol":2.2729,"impliedVolPercentile":0.72},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","floatShares":16089235,"roa":"-28.04%","roe":"-47.27%","lyrEps":-0.728135,"volumeRatio":1.1866023444132845,"shares":30984358,"dividePrice":0,"high":2.48,"amplitude":0.144186,"preClose":2.15,"low":2.17,"week52Low":1.14,"pbRate":"1.27","week52High":11.2,"institutionHeld":0,"latestPrice":2.43,"eps":-0.829901,"divideRate":0,"volume":342981,"delay":0,"ttmEps":-0.829901,"open":2.17,"prevYearClose":2.83,"prevWeekClose":1.98,"prevMonthClose":1.98,"prevQuarterClose":1.59,"fiveDayClose":1.98,"twentyDayClose":1.79,"sixtyDayClose":2.78},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SKYE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541074476","title":"Skye Bioscience Inc. Unveils Presentation on Innovative CB1 Antibody for Tackling Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2541074476","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541074476?lang=en_us&edition=fundamental","pubTime":"2025-06-05 23:56","pubTimestamp":1749138988,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. has released a corporate presentation detailing its developments in the field of obesity treatment. The company is working on pioneering the first CB1 antibody, nimacimab, which aims to address the needs of patients who do not respond to or cannot tolerate existing GLP-1 drugs. The presentation highlights the crowded nature of the GLP-1 space, noting issues with safety and adherence. It also discusses the opportunity for nimacimab to offer a combination option for additional weight loss. Skye Bioscience is focused on addressing fundamental drivers of metabolic diseases, such as increasing energy expenditure and targeting adipose tissue to reduce fat mass. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL5xcRDJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2536506770","title":"Skye Bioscience Inc - Data From 26-Week Treatment Period Expected Late Q3 or Early Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2536506770","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536506770?lang=en_us&edition=fundamental","pubTime":"2025-05-19 17:00","pubTimestamp":1747645249,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nTUA5NQ2CH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2536506767","title":"Skye Bioscience Establishes Partnership With Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2536506767","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536506767?lang=en_us&edition=fundamental","pubTime":"2025-05-19 17:00","pubTimestamp":1747645249,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nTUA5NQ2CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2536506700","title":"Skye Bioscience- to Fund Arecor's Development Activities With Option to License Rights to New Proprietary Formulation of Nimacimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2536506700","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536506700?lang=en_us&edition=fundamental","pubTime":"2025-05-19 17:00","pubTimestamp":1747645249,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nTUA5NQ2CH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2535304246","title":"Piper Sandler Sticks to Its Buy Rating for Skye Bioscience (SKYE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535304246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535304246?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:01","pubTimestamp":1747220484,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Skye Bioscience (SKYE – Research Report) today and set a price target of $20.00. T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-its-buy-rating-for-skye-bioscience-skye-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-its-buy-rating-for-skye-bioscience-skye-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKYE"],"gpt_icon":0},{"id":"2535082685","title":"BRIEF-Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535082685","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535082685?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:23","pubTimestamp":1747167815,"startTime":"0","endTime":"0","summary":"BRIEF-Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)May 13 (Reuters) - Skye Bioscience Inc SKYE.O:SKYE ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nGNX9X928cFurther company coverage: SKYE.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA90LXKY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2535719081","title":"Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535719081","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535719081?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:05","pubTimestamp":1747166701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA90LXKY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2534204132","title":"Oppenheimer Adjusts Skye Bioscience Price Target to $17 From $21, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2534204132","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534204132?lang=en_us&edition=fundamental","pubTime":"2025-05-12 20:57","pubTimestamp":1747054674,"startTime":"0","endTime":"0","summary":"Skye Bioscience (SKYE) has an average rating of Buy and mean price target of $16.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","SKYE"],"gpt_icon":0},{"id":"2534434833","title":"Piper Sandler Reaffirms Their Buy Rating on Skye Bioscience (SKYE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2534434833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534434833?lang=en_us&edition=fundamental","pubTime":"2025-05-09 23:19","pubTimestamp":1746803985,"startTime":"0","endTime":"0","summary":"In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Skye Bioscience (SKYE – Research Report), with a price ta...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-skye-bioscience-skye?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-skye-bioscience-skye?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKYE"],"gpt_icon":0},{"id":"2534316202","title":"Skye Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2534316202","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534316202?lang=en_us&edition=fundamental","pubTime":"2025-05-09 05:02","pubTimestamp":1746738151,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc reports results for the quarter ended March 31 - Earnings SummarySkye Bioscience Inc SKYE.OQ reported a quarterly adjusted loss of 28 cents per share for the quarter ended March 31","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nL8N3RG3MZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE"],"gpt_icon":0},{"id":"2534454166","title":"Skye Bioscience Q1 EPS $(0.28) Beats $(0.31) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2534454166","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534454166?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:07","pubTimestamp":1746734855,"startTime":"0","endTime":"0","summary":"Skye Bioscience (NASDAQ:SKYE) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.31) by 9.68 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45299566/skye-bioscience-q1-eps-0-28-beats-0-31-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE"],"gpt_icon":0},{"id":"2534611701","title":"Skye Bioscience Inc: Qtrly Loss per Share $0.28","url":"https://stock-news.laohu8.com/highlight/detail?id=2534611701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534611701?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:01","pubTimestamp":1746734461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA7YVJSC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2534161179","title":"Skye Bioscience Inc  Q1 Shr View $-0.29 -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2534161179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534161179?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:01","pubTimestamp":1746734461,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA7YVJSC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2534165702","title":"Press Release: Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2534165702","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534165702?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:01","pubTimestamp":1746734460,"startTime":"0","endTime":"0","summary":"-- Nimacimab in combination with tirzepatide improves weight loss effect. over tirzepatide alone, and shows comparable weight loss to monlunabant. and tirzepatide alone in preclinical diet-induced obesity model. -- In vitro data reported from new preclinical study highlights superior. potency of peripherally restricted CB1 inhibitor, nimacimab, versus. monlunabant when tested under pathological levels of CB1 agonists. -- Expanded preclinical study data to be presented at ADA in June 2025. -- Top-line data readout from CBeyond Phase 2a study of nimacimab. \"In Q1, we made decisive progress across clinical operations and R&D,\" said Punit Dhillon, President & CEO of Skye. \"Nimacimab continues to demonstrate a differentiated profile as a potential weight loss therapy, with a peripherally restricted mechanism that may set it apart from both GLP-1s and small-molecule CB1 inhibitors. We're advancing a body of preclinical and clinical evidence that supports its potential in reshaping the treatm","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","TM","SKYE","BK4099","BK4022","03160","BK4588","BK4232","BK4139","R","BK4604","BK4585"],"gpt_icon":0},{"id":"2533769839","title":"Skye Bioscience Inc  expected to post a loss of 29 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533769839","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533769839?lang=en_us&edition=fundamental","pubTime":"2025-05-07 05:07","pubTimestamp":1746565625,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc  expected to post a loss of29cents a share - Earnings Preview Skye Bioscience Inc SKYE.OQ SKYE.O is expected to show no change in quarterly revenue when it reports  results on May ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nL8N3RE3DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE"],"gpt_icon":0},{"id":"2531781957","title":"Skye Bioscience to Participate in May Investment and Medical Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2531781957","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531781957?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 29, 2025  -- Skye Bioscience, Inc.  , a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming healthcare conferences:. Citizens Life Sciences Conference Presentation, Thursday, May 8, 11:00 am ET + 1x1 meetings. Craig-Hallum Institutional Investor Conference 1x1 meetings, Wednesday, May 28. European Congress on Obesity Poster presentation, May 13. Available webcasts will be accessible on Skye’s website.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/skye-bioscience-participate-may-investment-110000233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2530650354","title":"Skye Bioscience announces inducement grant under Nasdaq listing rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2530650354","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530650354?lang=en_us&edition=fundamental","pubTime":"2025-04-28 05:35","pubTimestamp":1745789703,"startTime":"0","endTime":"0","summary":"Skye Bioscience (SKYE) announced that on April 23, 2025, the Board of Directors granted a non-qualified stock option award to purchase 19,000 share...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/skye-bioscience-announces-inducement-grant-under-nasdaq-listing-rule?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/skye-bioscience-announces-inducement-grant-under-nasdaq-listing-rule?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNQmain","TSYW.SI","IE00BGHQF748.EUR","NQmain","BK4112","SQQQ","PSQ","TQQQ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","QLD","USJW.SI","BK4588","USAW.SI","BK4585","SKYE","LU2210150020.SGD","IE00BKPKM429.USD","NDAQ","BK4139",".IXIC","QID","LU2210149790.SGD","NVIW.SI","LU2095319765.USD"],"gpt_icon":0},{"id":"2530197527","title":"Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2530197527","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530197527?lang=en_us&edition=fundamental","pubTime":"2025-04-26 08:06","pubTimestamp":1745625986,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250426:nTUA7J8G3P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2527425040","title":"BUZZ-U.S. STOCKS ON THE MOVE-Dow, Nike, Coty","url":"https://stock-news.laohu8.com/highlight/detail?id=2527425040","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527425040?lang=en_us&edition=fundamental","pubTime":"2025-04-16 01:53","pubTimestamp":1744739611,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Dow, Nike, CotyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refini.tv/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nL6N3QT0GU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEP","CTVA","ALB","HRL","CYTK","RDFN","XOM","NKE","LU2249611893.SGD","MTVA","COTY","EOSE","FMC","LU1223082519.USD","SKYE","PNC","BK4108","DOW","HWM","CAT","IE00B5949003.HKD","CVX","LU0795875086.SGD","CHD","NEM","IE00BBT3K403.USD","LU0788108826.HKD","HPE","AUR","SEDG","SPNT","VLO","LU2468319806.SGD","MP","LU1280957306.USD","LVS","AMAT","BK4109","FLNC","ACI","HUN","HXL","JNJ","ADM","CMPS"],"gpt_icon":1},{"id":"2527440976","title":"Skye Bioscience Stock Rises on Preclinical Data for Weight Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2527440976","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527440976?lang=en_us&edition=fundamental","pubTime":"2025-04-16 00:31","pubTimestamp":1744734660,"startTime":"0","endTime":"0","summary":"Shares of Skye Bioscience rose after the company announced promising preclinical data for a drug combination including its new CB1 antibody nimacimab.The stock was up 60% to $2.09 Tuesday. Shares have lost 84% over the past 12 months.The biotechnology company said nimacimab combined with tirzepatide resulted in greater than 30% weight loss for mice in a diet-induced obesity model over 25 days.Nimacimab alone demonstrated 24% weight loss, comparable with monlunabant and tirzepatide alone, the company said.Chief Executive Punit Dhillon said data supports the company's belief that its antibody approach can provide meaningful efficacy without the risk of unwanted neuropsychiatric side effects that come with small molecule CB1 inhibitors like monlunabant.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SKYE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"SKYE","fiscalQuarterEnding":"2025/03","expectedEps":-0.31,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.28},{"market":"US","date":"2025-03-20","symbol":"SKYE","fiscalQuarterEnding":"2024/12","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2024-11-07","symbol":"SKYE","fiscalQuarterEnding":"2024/09","expectedEps":-0.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2024-08-09","symbol":"SKYE","fiscalQuarterEnding":"2024/06","expectedEps":-0.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"post","actualEps":-0.2},{"market":"US","date":"2024-05-10","symbol":"SKYE","fiscalQuarterEnding":"2024/03","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"post","actualEps":-0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SKYE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SKYE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.7143,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7143,"analysts":7,"updateTime":1740715200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SKYE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SKYE","date":"2025-06-06","current":-2.040261,"percent":0.886029,"low":-12.94129,"twenty":-7.099247,"median":-4.06458,"eighty":-2.616276,"high":-1.399078,"avg":-4.74008,"sd":2.539269,"marketCap":66616369},"quantilePoints":[{"date":"2024-04-12","current":-9.459964,"twenty":-9.513638,"median":-9.459964,"eighty":-7.885539,"marketCap":356118289},{"date":"2024-04-19","current":-12.650558,"twenty":-12.435864,"median":-9.657512,"eighty":-9.495746,"marketCap":476227531},{"date":"2024-04-26","current":-9.579238,"twenty":-12.081022,"median":-9.691058,"eighty":-9.561347,"marketCap":360608354},{"date":"2024-05-03","current":-9.683603,"twenty":-11.635233,"median":-9.68733,"eighty":-9.561347,"marketCap":364537161},{"date":"2024-05-10","current":-8.997775,"twenty":-10.807766,"median":-9.638876,"eighty":-9.507673,"marketCap":338719287},{"date":"2024-05-17","current":-9.168,"twenty":-10.15772,"median":-9.601602,"eighty":-9.22813,"marketCap":343770610},{"date":"2024-05-24","current":-8.952556,"twenty":-9.700003,"median":-9.54942,"eighty":-8.9931,"marketCap":335692167},{"date":"2024-05-31","current":-8.720508,"twenty":-9.691058,"median":-9.489815,"eighty":-8.983995,"marketCap":326991116},{"date":"2024-06-07","current":-8.47349,"twenty":-9.691058,"median":-9.389145,"eighty":-8.952556,"marketCap":317728707},{"date":"2024-06-14","current":-8.069277,"twenty":-9.691058,"median":-9.18753,"eighty":-8.690567,"marketCap":302572037},{"date":"2024-06-21","current":-6.684476,"twenty":-9.685094,"median":-9.060284,"eighty":-8.473188,"marketCap":250646409},{"date":"2024-06-28","current":-5.434411,"twenty":-9.674658,"median":-9.022864,"eighty":-8.245631,"marketCap":203773004},{"date":"2024-07-05","current":-5.58412,"twenty":-9.638876,"median":-8.993879,"eighty":-7.844715,"marketCap":209386586},{"date":"2024-07-12","current":-4.873005,"twenty":-9.631421,"median":-8.980898,"eighty":-7.11863,"marketCap":182722074},{"date":"2024-07-15","current":-4.820607,"twenty":-9.62993,"median":-8.974213,"eighty":-6.892464,"marketCap":180757321},{"date":"2024-08-02","current":-4.102007,"twenty":-9.628439,"median":-8.967527,"eighty":-6.745055,"marketCap":153812130},{"date":"2024-08-09","current":-3.735222,"twenty":-9.606075,"median":-8.870216,"eighty":-5.58412,"marketCap":140058855},{"date":"2024-08-16","current":-3.615791,"twenty":-9.579238,"median":-8.690567,"eighty":-4.690361,"marketCap":152904981},{"date":"2024-08-23","current":-3.787972,"twenty":-9.567311,"median":-8.506414,"eighty":-4.17237,"marketCap":160186171},{"date":"2024-08-30","current":-4.584307,"twenty":-9.543456,"median":-8.189044,"eighty":-4.185844,"marketCap":193861673},{"date":"2024-09-06","current":-4.347559,"twenty":-9.525571,"median":-8.069277,"eighty":-4.204574,"marketCap":183850037},{"date":"2024-09-13","current":-4.304513,"twenty":-9.489808,"median":-7.545298,"eighty":-4.204574,"marketCap":182029740},{"date":"2024-09-20","current":-3.93863,"twenty":-9.483818,"median":-7.11863,"eighty":-4.170873,"marketCap":166557212},{"date":"2024-09-27","current":-2.840979,"twenty":-9.431636,"median":-6.35886,"eighty":-4.072065,"marketCap":120139628},{"date":"2024-10-04","current":-2.56836,"twenty":-9.296072,"median":-5.58412,"eighty":-3.802872,"marketCap":108611078},{"date":"2024-10-11","current":-2.683147,"twenty":-9.199248,"median":-5.224584,"eighty":-3.740033,"marketCap":113465204},{"date":"2024-10-18","current":-3.034682,"twenty":-9.153032,"median":-4.873005,"eighty":-3.308736,"marketCap":128330966},{"date":"2024-10-25","current":-3.501004,"twenty":-9.080009,"median":-4.593919,"eighty":-3.325954,"marketCap":148050855},{"date":"2024-10-31","current":-3.651662,"twenty":-9.02741,"median":-4.557114,"eighty":-3.343172,"marketCap":154421896},{"date":"2024-11-08","current":-7.770049,"twenty":-9.018318,"median":-4.55561,"eighty":-3.379043,"marketCap":165040297},{"date":"2024-11-15","current":-7.870031,"twenty":-8.997775,"median":-4.571462,"eighty":-3.501004,"marketCap":167163977},{"date":"2024-11-22","current":-5.956085,"twenty":-8.989983,"median":-4.820607,"eighty":-3.501004,"marketCap":126510669},{"date":"2024-11-29","current":-6.413147,"twenty":-8.983995,"median":-4.921494,"eighty":-3.53544,"marketCap":136218922},{"date":"2024-12-06","current":-5.070528,"twenty":-8.981218,"median":-5.25247,"eighty":-3.595703,"marketCap":107700929},{"date":"2024-12-13","current":-4.784865,"twenty":-8.970201,"median":-5.21336,"eighty":-3.614356,"marketCap":101633271},{"date":"2024-12-20","current":-4.084989,"twenty":-8.95555,"median":-5.042643,"eighty":-3.644488,"marketCap":86767509},{"date":"2024-12-27","current":-3.799325,"twenty":-8.952556,"median":-4.89725,"eighty":-3.64221,"marketCap":80699851},{"date":"2025-01-03","current":-4.070706,"twenty":-8.886684,"median":-4.82416,"eighty":-3.64221,"marketCap":86464126},{"date":"2025-01-10","current":-4.427785,"twenty":-8.774403,"median":-4.734873,"eighty":-3.64221,"marketCap":94048699},{"date":"2025-01-17","current":-3.856458,"twenty":-8.71452,"median":-4.60353,"eighty":-3.6441,"marketCap":81913383},{"date":"2025-01-24","current":-3.727909,"twenty":-8.690567,"median":-4.558618,"eighty":-3.651662,"marketCap":79182936},{"date":"2025-01-31","current":-5.356192,"twenty":-8.660625,"median":-4.557114,"eighty":-3.694707,"marketCap":113768587},{"date":"2025-02-07","current":-4.256387,"twenty":-8.539337,"median":-4.55561,"eighty":-3.699343,"marketCap":90408104},{"date":"2025-02-14","current":-4.370652,"twenty":-8.47349,"median":-4.466458,"eighty":-3.699343,"marketCap":92835167},{"date":"2025-02-21","current":-4.470635,"twenty":-8.472282,"median":-4.477777,"eighty":-3.722196,"marketCap":94958847},{"date":"2025-02-28","current":-3.827892,"twenty":-8.245631,"median":-4.442068,"eighty":-3.730044,"marketCap":81306617},{"date":"2025-03-07","current":-3.670777,"twenty":-8.162365,"median":-4.40636,"eighty":-3.699343,"marketCap":77969405},{"date":"2025-03-14","current":-3.463671,"twenty":-8.134468,"median":-4.354733,"eighty":-3.698416,"marketCap":73570353},{"date":"2025-03-21","current":-2.203547,"twenty":-8.081254,"median":-4.304513,"eighty":-3.649772,"marketCap":58541914},{"date":"2025-03-28","current":-2.471704,"twenty":-7.90988,"median":-4.297339,"eighty":-3.6255,"marketCap":65666062},{"date":"2025-04-04","current":-1.632257,"twenty":-7.858605,"median":-4.256387,"eighty":-3.582221,"marketCap":43364381},{"date":"2025-04-11","current":-1.562303,"twenty":-7.846922,"median":-4.225597,"eighty":-3.501004,"marketCap":41505907},{"date":"2025-04-17","current":-1.842119,"twenty":-7.799915,"median":-4.189726,"eighty":-3.364695,"marketCap":48939801},{"date":"2025-04-25","current":-2.086958,"twenty":-7.727199,"median":-4.165203,"eighty":-3.259602,"marketCap":55444458},{"date":"2025-05-02","current":-2.366773,"twenty":-7.630073,"median":-4.156405,"eighty":-3.056205,"marketCap":62878352},{"date":"2025-05-09","current":-1.698098,"twenty":-7.560926,"median":-4.127838,"eighty":-2.911286,"marketCap":55444458},{"date":"2025-05-16","current":-1.907406,"twenty":-7.545298,"median":-4.116978,"eighty":-2.799369,"marketCap":62278559},{"date":"2025-05-23","current":-1.964344,"twenty":-7.500386,"median":-4.077848,"eighty":-2.746856,"marketCap":64137621},{"date":"2025-05-30","current":-2.011792,"twenty":-7.329718,"median":-4.070706,"eighty":-2.683147,"marketCap":65686838},{"date":"2025-06-06","current":-2.040261,"twenty":-7.099247,"median":-4.06458,"eighty":-2.616276,"marketCap":66616369}],"updateTime":1749313149044}}}